Find Clinical Trial

Evaluation of the anti-anginal efficacy and safety of oral administration of ivabradine compared to placebo on top of a background therapy with atenolol in patients with stable angina pectoris. A 4-month randomised double-blind parallel-group international multicentre study.


← Back
Study Phase

Phase 3

Therapeutic Area

Cardiovascular Diseases

IndicationCoronary Artery Disease
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device

IVABRADINE,
S016257

Active Substance CodeS016257
Protocol CodeCL3-16257-057
EudraCT Code2004-001960-30
NCT CodeNCT00202566


Documents and links

Results summary READ MORE
Scientific publication READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2024 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility